Skip to content

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Phase II Study Examining the Biological Efficacy of Intratumoral INGN 241 (Ad-mda7) Administration in Patients With In Transit Melanoma

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00116363
Enrollment
25
Registered
2005-06-29
Start date
2005-03-31
Completion date
2006-12-31
Last updated
2008-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Melanoma, Neoplasm Metastasis

Keywords

gene therapy, melanoma, adenovirus, in-transit melanoma, metastatic melanoma

Brief summary

This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.

Detailed description

INGN 241 is an adenoviral vector carrying the MDA-7 cDNA. MDA-7 is a novel tumor suppressor molecule with cytokine properties, recently designated as IL-24. Over expression of MDA-7 in melanoma cells in vitro has been shown to inhibit cellular proliferation and induce apoptosis. Loss of MDA-7 expression in human melanomas has been shown to correlate with invasion and metastasis. The INGN 241 gene transfer construct has been previously used in human subjects in an ongoing open label Phase I study using intratumoral administration, and has been well tolerated to date. The primary objectives of the present study are to determine if INGN 241, injected into a melanoma in transit lesion, can induce apoptosis in regional uninjected lesions and initiate systemic immune activation. Secondary objectives include examination of specific immunity and of clinical response and toxicity.

Interventions

GENETICinvestigational drug INGN 241

Sponsors

M.D. Anderson Cancer Center
CollaboratorOTHER
Introgen Therapeutics
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically proven melanoma, must have 3 regional metastatic lesions that are in transit

Exclusion criteria

* Central nervous system involvement by melanoma

Design outcomes

Primary

MeasureTime frame
anti-tumor effects and systemic immune activation at 28 days

Secondary

MeasureTime frame
tumor response
toxicity and safety
the induction of antigen-specific T-lymphocytes after multiple cycles of treatment

Countries

United States

Contacts

Primary ContactKevin B Kim, MD
800.392.1611

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026